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China is experiencing the most severe dengue outbreak 
since the 1980s. Till 31 October 2014, a total of 44497 la-
boratory-confirmed dengue cases with six deaths have been 
reported in mainland China, among which 43031 cases were 
from Guangdong. Although dengue fever is classified as a 
notifiable infectious disease according to Chinese Ministry 
of Health, the public and health care system has not fully 
appreciated the medical burden of this disease. The unprec-
edented dengue cases in China have set off the alarm for 
public health to respond to emerging and re-emerging dis-
eases. A comprehensive strategy is needed to win the battle 
against dengue and other infectious diseases, including sur-
veillance, diagnostics, vector control, vaccine, and drug 
development.  
Dengue is not a new infectious disease in China. The 
disease is caused by dengue virus (DENV) infection. It was 
first described in the medical encyclopaedia “TAI PING 
SHENG HUI FANG” in Song dynasty. Large outbreaks of 
dengue fever were well recorded in China during World 
War II; the disease disappeared for the next 30 years and 
re-emerged in the 1980s in southern China. For the past few 
decades, only sporadic outbreaks and imported cases were 
reported in China. Guangdong province is the major affect-
ed areas, and some Guangzhou indigen called it “broken-
bone fever” or “mosquito-bite disease”.  
The current dengue problem in China is a reflection of 
global situation. Nowadays, dengue is well regarded as the 
most prevalent mosquito-borne viral disease in humans. 
Half of global population lives at areas at risk of dengue 
infection. An estimate of 390 million individuals was in-
fected by DENV in more than 100 countries. Dengue activ-
ity has increased substantially in many tropical and sub-
tropical countries due to globalization, climate change, en-
vironmental deterioration, and social factors. USA, Europe, 
and Japan have recently suffered their first autochthonous 
dengue outbreak [1].  
Dengue has largely changed its appearance in China, and 
current situation is more complex than thought. Dengue is a 
typical mosquito-transmitted viral disease caused by the 
four serotypes of DENV, which belongs to the genus Fla-
vivirus within the family of Flaviviradae. Aedes aegypti and 
Aedes albopictus are the major mosquito vectors; the later 
mosquito is widely distributed in mainland China. Dengue 
outbreaks in Guangdong are usually seasonal with de-
creased or no cases in winter. However, people are worry-
ing about the re-emergence of outbreaks in the following 
years. Aedes albopictus, the primary vector for DENV in 
Guangdong, can transmit DENV transovarially, thus over-
wintering mosquitoes may serve as potential source of den-
gue to initiate a new infection cycle. Importantly, Aedes 
aegypti, the more effective DENV vector than Aedes al-
bopictus, has been introduced and colonized southern re-
gions of China, including Yunnan and Guangdong provinc-
es [2]. It is likely that DENV will establish its infection in 
Chinese Aedes aegypti, which can further deteriorate the 
current situation. Extensive and long-term vector control is 
needed to mitigate the situation. 
After this large outbreak, it is possible that DENV will be 
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endemic in southern China, especially in Guangdong. All 
four serotypes of DENV have been isolated during the past 
10 years. The co-circulation of multiple serotypes of DENV 
increases the risk of severity of disease. Genomic sequence 
analysis of the newly isolated DENV-2 in Guangzhou dur-
ing this outbreak demonstrated high homology to the ones 
isolated in the past decade in Guangdong [3]. Individuals 
that have been exposed to DENV-2 this year are prone to 
development of severe disease when infected with a sec-
ondary heterotypic DENV infection, due to the phenomena 
of antibody-dependent enhancement of infection. Severe 
dengue cases caused by secondary heterotypic DENV have 
been documented, and the proportion of secondary infection 
among severe cases is increasing during recent outbreaks in 
Guangdong (personal communication).  
The geographic expansion of dengue disease in China 
remains to be closely monitored. It is likely that dengue 
epidemic will continue to spread to many southern provinc-
es, including Guangdong, Yunnan, Guangxi, Hainan, and 
Fujian. China has to be well prepared. Although the virus 
has been identified for more than 60 years, no approved 
vaccine and antiviral is currently available. Promising vac-
cine and antiviral drug candidates are being developed. The 
leading CYD dengue vaccine from Sanofi Pasteur is ex-
pected to be licensed in 2015 [4]. However, it should be 
noted that the CYD vaccine has weak protection against 
DENV-2. It will take some time to introduce such vaccine 
to China. Although a few compounds have been tested in 
dengue clinical trials, none of them have shown antiviral 
activity or clinical benefits in dengue patients [5]. More 
efforts are needed to develop bona fide antiviral drugs for 
dengue. The first molecular diagnosis kit targeting DENV 
genome has just been approved by Chinese Food and Drug  
Administration. The point-of-care diagnosis kit targeting the 
NS1 protein is critically needed in clinics.  
Dengue is now turning into a long-term threat in South-
ern China. There is an urgent need for continued research 
into the diagnosis, pathogenesis, prevention, and treatment 
of DENV infections. Like many infectious diseases, patho-
gens have been evolutionarily evolving with the hosts [6]. 
To fight them, we humans have to keep sharpening our ar-




1 Guzman MG, Harris E. Dengue. Lancet, 2014, 14: 60572–60579 
2 Zhang FC, Zhao H, Li LH, Jiang T, Hong WX, Wang J, Zhao LZ, 
Yang HQ, Ma DH, Bai CH, Shan XY, Deng YQ, Qin CF. Severe 
dengue outbreak in Yunnan, China, 2013. Int J Infect Dis, 2014, 27: 
4–6 
3 Zhao H, Zhao LZ, Jiang T, Li XF, Fan H, Hong WX, Zhang Y, Zhu 
Q, Ye Q, Tong YG, Cao WC, Zhang FC, Qin CF. Isolation and 
characterization of dengue virus serotype 2 from the large dengue 
outbreak in Guangdong, China in 2014. Sci China Life Sci, 2014, 57: 
1149–1155 
4 Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, 
Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan 
DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der 
Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, 
Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A. Clinical 
efficacy and safety of a novel tetravalent dengue vaccine in healthy 
children in Asia: a phase 3, randomised, observer-masked, 
placebo-controlled trial. Lancet, 2014, 384: 1358–1365 
5 Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa 
F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. Ten years of dengue 
drug discovery: progress and prospects. Antiviral Res, 2013, 100: 
500–519 
6 Li J, Yu XF, Pu XY, Xie L, Sun YX, Xiao HX, Wang FJ, Din H, Wu 
Y, Liu D, Zhao GQ, Liu J, Pan JC. Environmental connections of 
novel avian-origin H7N9 influenza virus infection and virus adapta-
tion to the human. Sci China Life Sci, 2013, 56: 485–492 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
